Alexion Pharmaceuticals

Part of AstraZeneca (Wikidata)

CompanyUnited StatesFounded 1992

Alexion Pharmaceuticals develops one asset, in phase 3 (ravulizumab in IgAN). Mostly antibody acting on inflammation and C5; based in the United States, founded in 1992.

1
Asset
Furthest: Phase 3; 12
Trials: 0
Signals

Pipeline

ravulizumab
Monoclonal antibody that inhibits terminal complement component C5
Phase 3, Antibody, Inflammation, C5, IgAN, immunoglobulin a nephropathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

Evidence behind the mechanisms2
Trials14
Signals1
Integrity notices4
Similar companies6

Updated 8 Oct 2026 · 16 sources